Revolution Medicines, Inc.
RVMD
Rang in Aktien
#619
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Aktienkurs
$187.63
Marktkapitalisierung
$40.22B
Veränderung (1 Tag)
3.01%
Veränderung (1 Jahr)
247.40%
Land
US
Handel Revolution Medicines, Inc. (RVMD)
Kategorie
Healthcare
Gewinn für Revolution Medicines, Inc. (RVMD)
Gewinn im Jun 2026 TTM: $-1.77B
Laut den aktuellen Finanzberichten von Revolution Medicines, Inc. betragen die aktuellen Gewinne des Unternehmens $-1.77B. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $-439.89M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2022, der $-249.13M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Revolution Medicines, Inc. von 2017 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $-1.77B | 194.30% |
| 2024 | $-600.85M | 36.59% |
| 2023 | $-439.89M | 76.57% |
| 2022 | $-249.13M | 33.16% |
| 2021 | $-187.09M | 72.39% |
| 2020 | $-108.53M | 108.56% |
| 2019 | $-52.04M | 24.52% |
| 2018 | $-41.79M | 34.25% |
| 2017 | $-31.13M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | -398.31% |
US
|
|
| $-3.09B | 74.58% |
US
|
|
| $-4.02B | 127.12% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -210.31% |
NL
|
